You are here

Article info

Article menu
XML
Oncolytic and local immunotherapy
Original research
In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy

Authors

  • Yinwen Cheng Interdisciplinary Graduate Program in Human Toxicology, The University of Iowa, Iowa City, Iowa, USA Department of Pathology, The University of Iowa, Iowa City, Iowa, USA Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa, USA PubMed articlesGoogle scholar articles
  • Caitlin D Lemke-Miltner Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa, USA Department of Internal Medicine, The University of Iowa, Iowa City, Iowa, USA PubMed articlesGoogle scholar articles
  • Wattawan Wongpattaraworakul Department of Pathology, The University of Iowa, Iowa City, Iowa, USA Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa, USA Department of Oral Pathology, Radiology and Medicine, College of Dentistry, The University of Iowa, Iowa City, Iowa, USA PubMed articlesGoogle scholar articles
  • Zhaoming Wang Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa, USA Department of Internal Medicine, The University of Iowa, Iowa City, Iowa, USA Cancer Biology Program, The University of Iowa, Iowa City, Iowa, USA PubMed articlesGoogle scholar articles
  • Carlos H F Chan Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa, USA Cancer Biology Program, The University of Iowa, Iowa City, Iowa, USA Department of Surgery, The University of Iowa, Iowa City, Iowa, USA PubMed articlesGoogle scholar articles
  • Aliasger K Salem Interdisciplinary Graduate Program in Human Toxicology, The University of Iowa, Iowa City, Iowa, USA Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa, USA Cancer Biology Program, The University of Iowa, Iowa City, Iowa, USA Department of Pharmaceutical Sciences and Experimental Therapeutics, The University of Iowa College of Pharmacy, Iowa City, Iowa, USA PubMed articlesGoogle scholar articles
  • George J Weiner Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa, USA Department of Internal Medicine, The University of Iowa, Iowa City, Iowa, USA Cancer Biology Program, The University of Iowa, Iowa City, Iowa, USA PubMed articlesGoogle scholar articles
  • Andrean L Simons Interdisciplinary Graduate Program in Human Toxicology, The University of Iowa, Iowa City, Iowa, USA Department of Pathology, The University of Iowa, Iowa City, Iowa, USA Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa, USA Department of Oral Pathology, Radiology and Medicine, College of Dentistry, The University of Iowa, Iowa City, Iowa, USA Cancer Biology Program, The University of Iowa, Iowa City, Iowa, USA Department of Pharmaceutical Sciences and Experimental Therapeutics, The University of Iowa College of Pharmacy, Iowa City, Iowa, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr. Andrean L Simons; andrean-simons{at}uiowa.edu
View Full Text

Citation

Cheng Y, Lemke-Miltner CD, Wongpattaraworakul W, et al
In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy
Journal for ImmunoTherapy of Cancer 2020;8:e000940. doi: 10.1136/jitc-2020-000940

Publication history

  • Accepted September 7, 2020
  • First published October 15, 2020.
Online issue publication 
October 15, 2020

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.